ArticleJournal of the National Cancer Institute2026
Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and Safety of PD-1 Inhibitor-Based Regimens in Patients with Melanoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3) was approved for advanced melanoma in 2016. The CheckMate 511 trial demonstrated improved tolerability with the flipped dose, NIVO3+IPI1, but this regimen has not been approved in melanoma by regulatory authorities. In this study, patients with advanced unresectable melanoma treated with NIVO3+IPI1 or NIVO1+IPI3 were included. The objective response rate was 48.8% with NIVO3+IPI1 (n = 209) and 36.9% with NIVO1+IPI3 (n = 190) (P = .016). Adjusted hazard ratio (aHR) was 0.67 (95% CI = 0.53 to 0.87, P = .002) for progression-free survival and 0.59 (95% CI = 0.44 to 0.78, P < .001) for overall survival (OS). In most studied subgroups aHR was <1, in favor of NIVO3+IPI1. The incidence of grade 3-5 immune-related adverse events was 30.6% with NIVO3+IPI1 vs. 51.1% with NIVO1+IPI3 (P < .001). This study shows that in a real-world setting, NIVO3+IPI1 demonstrated superior efficacy compared with NIVO1+IPI3, possibly related to a beneficial safety and tolerability profile allowing for more received doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.